ATI 7505 clinical trials
Also written ATI-7505.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How each study uses ATI 7505 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Procter and Gamble (2) · Dr. Falk Pharma GmbH (1) · Mayo Clinic (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses ATI 7505 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Different Doses of Naronapride vs. Placebo in GastroparesisCompletedPhase 2Dr. Falk Pharma GmbHNCT05621811Written as NaronaprideHow we know
- Effect of ATI-7505 on Gastrointestinal Transit in Healthy VolunteersCompletedPhase 1/2Mayo ClinicNCT01094821Written as ATI-7505How we know
- Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic ConstipationTerminatedPhase 2Procter and GambleNCT00501241Written as ATI-7505How we know
- A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress SyndromeTerminatedPhase 2Procter and GambleNCT00630370Written as 20 mg ATI 7505How we know
Codes
What other systems call ATI 7505 · ClinicalTrials.gg INT005039
- MeSH (NLM) C517618ATI 7505Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 058896B00BNARONAPRIDEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C517618 | ATI 7505 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 058896B00B | NARONAPRIDE | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.